Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2300642 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Colleen R Foley und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Neoplasms, Vaccines, Cancer Vaccines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Cancer Institute (NCI), HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).
Abstract (Originalsprache)
The use of a patient’s own immune or tumor cells, manipulated ex vivo, enables Ag- or patient-specific immunotherapy. Despite some clinical successes, there remain significant barriers to efficacy, broad patient population applicability, and safety. Immunotherapies that target specific tumor Ags, such as chimeric Ag receptor T cells and some dendritic cell vaccines, can mount robust immune responses against immunodominant Ags, but evolving tumor heterogeneity and antigenic downregulation can drive resistance. In contrast, whole tumor cell vaccines and tumor lysate-loaded dendritic cell vaccines target the patient’s unique tumor antigenic repertoire without prior neoantigen selection; however, efficacy can be weak when lower-affinity clones dominate the T cell pool. Chimeric Ag receptor T cell and tumor-infiltrating lymphocyte therapies additionally face challenges related to genetic modification, T cell exhaustion, and immunotoxicity. In this review, we highlight some engineering approaches and opportunities to these challenges among four classes of autologous cell therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL.
- Committee on Immunology, University of Chicago, Chicago, IL.
- Ben May Department for Cancer Research, University of Chicago, Chicago, IL.
ORCID-Profile: Colleen R Foley, Sheridan L Swan
Förderung
- NIAID NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- NCI NIH HHS
Zitieren
APA
Foley, C. R., Swan, S. L., & Swartz, M. A. (2024). Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300642
Vancouver
Foley CR, Swan SL, Swartz MA. Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300642
BibTeX
@article{Foley2024,
author = {Foley, Colleen R and Swan, Sheridan L and Swartz, Melody A},
title = {Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2300642}
}
EUVIMED